Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation.

Slides:

Advertisements

Similar presentations

Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib C. Leitner, R. von Moos,

Advertisements

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long- term Survivor with Metastatic Non–Small-Cell Lung Cancer Kristin N.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Akos Varga-Szemes, MD, PhD, U. Joseph Schoepf, MD, Laura S

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous.

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Height Loss and Generalized Pain in a 35-year-old Man

Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non– small-cell Lung Cancer Exhibiting Resistance to Ceritinib Gouji Toyokawa,

An Uncommon Presentation of Brain Metastases in a Lung Cancer Patient

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion Eckart Laack, MD, Ronald.

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status Young Joo Lee, MD, Heung Tae Kim, MD,

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Nikolaas De Maeyer, MD, Walter De Wever, MD, PhD, Christophe M

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients Jangchul Park, MD, Chiaki Kondo, MD, Junichi.

A Severe Photosensitivity Dermatitis Caused by Crizotinib

Multiple Pulmonary Chondroid Hamartoma

Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist Kitty Huang, MSc, MDCM, David A. Palma,

Vipul Pareek, MD, Mary Welch, MD, Elizabeth Ravera, RN, Richard L

CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment

Bilateral Subdural Hematoma Associated with Central Nervous System Metastases from Lung Cancer Akito Hata, MD, Shiro Fujita, MD, PhD, Nobuyuki Katakami,

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib

Do Complex Mutations of the Epidermal Growth Factor Receptor Gene Reflect Intratumoral Heterogeneity? Akito Hata, MD, Shiro Fujita, MD, PhD, Reiko Kaji,

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer

Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement Denis Maillet, MD, Isabelle Martel-Lafay,

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor–Mutated Lung Cancer Treated with Two Cycles of Erlotinib Brendan.

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report

The Role of Surgery in the Management of Primary Thymic Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Kimihiro Shimizu, MD, PhD, Izumi Takeyoshi,

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

First Case of A859T Epidermal Growth Factor Receptor Mutation Responding to Erlotinib Laureline Le Maignan, BM, Delphine Mirebeau-Prunier, MD, PhD, Laurent.

A Case of Nontuberculous Mycobacteria Highly Suspected as Lung Cancer Invading the Aortic Arch Tadashi Umehara, MD, Masaya Aoki, MD, PhD, Aya Harada,

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

S768I Mutation in EGFR in Patients with Lung Cancer

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

Matthew Reichert, MD, Eric S. Bensadoun, MD

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC Francesco Gelsomino, MD, Valentina.

Marianna Koczywas, MD, Mihaela C. Cristea, MD

Daniel B. Costa, MD, PhD, Susan E. Jorge, PhD, Jason P

Presentation of Garcin Syndrome due to Lung Cancer

Recurrent Primary Synovial Sarcoma of the Chest Wall

Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers,

Metastatic Lung Cancer to the Pancreas

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

Focal Cholesterol Granuloma in the Anterior Mediastinum: [18F]-Fluoro-2-Deoxy-D- Glucose-Positron Emission Tomography and Magnetic Resonance Imaging Findings

Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern.

Complete and Durable Response of Choroid Metastasis from Non-small Cell Lung Cancer with Systemic Bevacizumab and Chemotherapy Ben George, MD, William.

Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib Tatsuya.

Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure Joel P. Womack,

Miliary Brain Metastases in a Patient with ROS1-Rearranged Lung Adenocarcinoma: A Case Report Katarzyna Dziadziuszko, MD, Edyta Szurowska, MD, PhD, Joanna.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor Britta Weber, MD, Michael Winterdahl, MMSc, Ashfaque Memon, MD, PhD, Boe S. Sorensen, PhD, Susanne Keiding, MD, DMSc, Leif Sorensen, MD, Ebba Nexo, MD, DMSc, Peter Meldgaard, MD, PhD Journal of Thoracic Oncology Volume 6, Issue 7, Pages 1287-1289 (July 2011) DOI: 10.1097/JTO.0b013e318219ab87 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Computed tomography of the chest before (A) and 3 weeks after start of treatment with erlotinib (B) of a 32-year-old woman diagnosed with non-small cell lung cancer with brain metastases who harbored an exon 19 mutation. Arrows indicate the tumor sites. Journal of Thoracic Oncology 2011 6, 1287-1289DOI: (10.1097/JTO.0b013e318219ab87) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Two axial magnetic resonance imaging of the brain before (A) and 3 weeks after start of treatment (B) of a 32-year-old woman diagnosed with non-small cell lung cancer and brain metastases harboring an exon 19 mutation. Arrows indicate positions of brain metastases. Journal of Thoracic Oncology 2011 6, 1287-1289DOI: (10.1097/JTO.0b013e318219ab87) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Gadolinium-enhanced T1-weighted magnetic resonance imaging (MRI) (A) coregistered with [11C]-erlotinib positron emission tomography (PET) (sum image, 5–60 minutes after tracer administration) (B) of a 32-year-old woman diagnosed with non-small cell lung cancer and brain metastases harboring an exon 19 mutation. The selected MRI image shows two metastatic lesions in the cerebellum. The [11C]-erlotinib PET image shows abnormal accumulation in focal areas corresponding to the two lesions on the MRI scan. Note the absence of [11C]-erlotinib accumulation in normal brain tissue. Journal of Thoracic Oncology 2011 6, 1287-1289DOI: (10.1097/JTO.0b013e318219ab87) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions